Acromegaly News Today

In this episode of Going Ringside we explore the end of Andre The Giant's life. Andre Roussimoff passed away at the relatively young age of 46 in 1993. His gigantism (acromegaly) played a substantial role in his failing health. We speak with a doctor about how that affected his life and if things could have been different if he had better medical care as a young man. We also explore how Andre was able to consume so much alcohol. At the end of the episode we also will have a WrestleMani...

The prospect of a looming recession has been in the background for a while now. Financial prognosticators have generally agreed that one will hit eventually, although its timing and magnitude remain open to debate. But for those concerned about a recession’s impact on the economy and the markets, one legendary Wall Street name has a reassuring take on the matter. Billionaire Steve Cohen, who runs hedge fund Point72 Asset Management, a firm with $31.4 billion of assets under management, ex...

Researchers delve into endocrine causes of hypertension (HTN), revealing key culprits like primary aldosteronism and Cushing's syndrome. The study also evaluates the efficacy of various treatments, offering valuable insights for tackling this widespread health issue.

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

The majority of patients with acromegaly who switched from therapy with injected somatostatin receptor ligands to Crinetics Pharmaceuticals Inc.’s once-daily, oral drug paltusotine maintained stable levels of insulin-like growth factor 1 in a phase III trial, moving the company’s first-in-class lead closer to becoming the potential new standard of care for the rare hormonal disorder.

Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern TimeSAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment bu

LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today

- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard

European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3... | December 5, 2022

Sweden: Coexistence of diabetes increases the risk of overall mortality as well as cardiovascular mortality and morbidity in patients with acromegaly, states a study article published in the Journal...